ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1632

Evidence-based Consensus Statements for the Identification and Management of Interstitial Lung Disease in Systemic Sclerosis

Anna-Maria Hoffmann-Vold1, Toby M. Maher 2, Edward E. Philpot 3, Ali Ashrafzadeh 4 and Oliver Distler 5, 1Dept. of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, 2National Heart and Lung Institute, Imperial College London; Interstitial Lung Disease Unit, Royal Brompton Hospital, London, UK, London, United Kingdom, 3Respiratory Center of Excellence, IQVIA, Durham, NC, USA, Durham, NC, 4Rheumatology Center of Excellence, IQVIA, San Diego, CA, USA, San Diego, CA, 5Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: interstitial lung disease and SSc-ILD, Systemic sclerosis

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Monday, November 11, 2019

Session Title: Systemic Sclerosis & Related Disorders – Clinical Poster II

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Guidelines are needed to aid early recognition and treatment of interstitial lung disease in systemic sclerosis (SSc-ILD). This study was conducted to develop expert consensus statements for the identification and management of SSc-ILD.

Methods: Evidence-based consensus statements were established using a modified Delphi process based on a systematic literature analysis. An expert panel of 27 European-based pulmonologists, rheumatologists and internists participated in three rounds of online surveys, a face-to-face discussion and a WebEx meeting, to establish statements and define an SSc-ILD management algorithm.

Results: The final evidence-based consensus included detailed statements on screening and risk stratification, diagnosis, assessment of severity, treatment options, monitoring, assessment of progression and treatment escalation. The consensus management algorithm is presented here in an abbreviated form for clinical use (figure).

Conclusion: These evidence-based expert consensus statements, developed using a modified Delphi process, provide important guidance for the identification and management of SSc-ILD in clinical practice.

Acknowledgements: The steering committee members would like to thank the expert panellists who participated in this study: Jérôme Avouac; Gianluca Bagnato; Rafic Barake; Simone Barsotti; Cosimo Bruni; Paolo Carducci; Patricia E Carreira; Ivan Castellví; Francesco Del Galdo; Jörg H W Distler; Ivan Foeldvari; Paolo Fraticelli; Peter M George; Bridget Griffiths; Alfredo Guillén-Del-Castillo; Abdul Monem Hamid; Bernhard Hellmich; Rudolf Horváth; Michael Hughes; Michael Kreuter; Belén López-Muñiz; Florentine Moazedi-Fuerst; Jacek Olas; Suman Paul; Cinzia Rotondo; Manuel Rubio-Rivas; Andrei Seferian; Michal Tomčík; Yurdagül Uzunhan; Ulrich A Walker; and Ewa Więsik-Szewczyk. The steering committee was chaired by John Cole (IQVIA, London, UK); the modified Delphi process was managed by Laura Wilson (IQVIA, Reading, UK). Medical writing support was provided by Rebecca Sutch, PhD, on behalf of AMICULUM Ltd, Oxford, UK.

 Funding: Boehringer Ingelheim International GmbH, Germany


Delphi fig pdf

Clinical management algorithm for SSc-ILD


Disclosure: A. Hoffmann-Vold, Actelion, 2, 5, Boehringer Ingelheim, 2, 5, GSK, 2, 5; T. Maher, GSK, 2, 5, UCB, 2, 5, Boehringer Ingelheim, 2, 5, AstraZeneca, 2, 5, Roche, 2, 5, Bayer, 2, 5, Biogen Idec, 2, 5, Cipla, 2, 5, Prometic, 2, 5, Sanumed, 2, 5, Apellis, 4; E. Philpot, IQVIA, 3; A. Ashrafzadeh, IQVIA, 3; O. Distler, A. Menarini, 5, Abbvie, Acceleron, 5, Acceleron Pharma, 5, Actelion, 2, 5, 8, Actelion Pharmaceuticals, 2, 5, 8, 9, Amgen, 5, AnaMar, 2, 5, Bayer, 2, 5, 8, 9, Biogen Idec, 2, 5, Blade Therapeutics, 5, Boehringer Ingelheim, 2, 5, 8, 9, Catenion, 5, 9, ChemomAb, 2, 5, ChemomAB, 5, CSL Behring, 5, Ergonex, 5, espeRare Foundation, 2, 5, Genentech/Roche, 2, 5, GlaxoSmithKline, 5, GSK, 2, 5, Holds Patent mir-29 for the treatment of systemic sclerosis, 9, Inventiva, 2, 5, iQvia, 5, Italfarmaco, 2, 5, Italfarmco, 5, Lilly, 2, 5, med, 5, 8, medac, 5, Medac, 2, 5, MedImmune, 2, 5, Medscape, 5, 8, 9, Menarini, 8, Mepha, 8, Mitsubishi Tanabe, 2, 5, Mitsubishi Tanabe Pharma, 2, 5, MSD, 5, 8, Novartis, 2, 5, 8, 9, Patent, 9, Patent issued, 9, Pfizer, 2, 5, 8, Pharmacyclics, 2, 5, Roche, 5, 8, 9, Sanofi, 2, 5, Sinoxa, 2, 5, Target Bio Science, 5, Target BioScience, 5, UCB, 2, 5, 9, UCB in the area of potential treatments of scleroderma and its complications, 2, 5.

To cite this abstract in AMA style:

Hoffmann-Vold A, Maher T, Philpot E, Ashrafzadeh A, Distler O. Evidence-based Consensus Statements for the Identification and Management of Interstitial Lung Disease in Systemic Sclerosis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/evidence-based-consensus-statements-for-the-identification-and-management-of-interstitial-lung-disease-in-systemic-sclerosis/. Accessed January 16, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/evidence-based-consensus-statements-for-the-identification-and-management-of-interstitial-lung-disease-in-systemic-sclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.